Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
Table 2
Meta-analysis of PRDX-1 and clinicopathological features in solid tumors patients.
Categories
Trials (patients)
OR (95% CI)
Age (young vs. old)
15 (2564)
0.99 (0.73-1.36)
62.4%
0.001
0.04
0.966
Gender (male vs. female)
13 (1543)
0.93 (0.74-1.17)F
21.5%
0.226
0.65
0.514
Tumor size (small vs. large)
12 (1907)
1.69 (1.07-2.68)
77.8%
<0.001
2.24
0.025
TNM stage (I+II vs. III+IV)
14 (2110)
2.26 (1.24-4.13)
87.3%
<0.001
2.65
0.008
Depth of invasion (T1+T2 vs. T3+T4)
4 (567)
1.11 (0.37-3.38)
87.1%
<0.001
0.18
0.854
Lymph node metastasis (negative vs. positive)
10 (1847)
1.47 (0.93-2.34)
76.9%
<0.001
1.64
0.100
Distant metastasis (negative vs. positive)
2 (174)
1.94 (0.84-4.47)F
26.9%
0.242
1.55
0.120
Degree of differentiation (poor/not vs. well/moderate)
7 (808)
0.59 (0.44-0.81)F
21.2%
0.268
3.33
0.001
All pooled ORs were calculated from random-effect model except for cells marked with (fixedF). denotes value for heterogeneity based on test; denotes value for statistical significance based on test. OR, odds ratio; CI, confidence interval.
